- Home
- PDS vs REPL Comparison
PDS vs REPL Comparison
Compare PDS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- REPL
- Stock Information
- Founded
- PDS 1951
- REPL 2015
- Country
- PDS Canada
- REPL United States
- Employees
- PDS N/A
- REPL N/A
- Industry
- PDS
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PDS
- REPL Health Care
- Exchange
- PDS Nasdaq
- REPL Nasdaq
- Market Cap
- PDS 872.2M
- REPL 780.3M
- IPO Year
- PDS N/A
- REPL 2018
- Fundamental
- Price
- PDS $58.29
- REPL $14.01
- Analyst Decision
- PDS Buy
- REPL Strong Buy
- Analyst Count
- PDS 1
- REPL 6
- Target Price
- PDS $95.00
- REPL $19.67
- AVG Volume (30 Days)
- PDS 76.9K
- REPL 816.7K
- Earning Date
- PDS 02-12-2025
- REPL 02-14-2025
- Dividend Yield
- PDS N/A
- REPL N/A
- EPS Growth
- PDS 62.11
- REPL N/A
- EPS
- PDS 12.37
- REPL N/A
- Revenue
- PDS $1,436,787,445.00
- REPL N/A
- Revenue This Year
- PDS $2.38
- REPL N/A
- Revenue Next Year
- PDS $2.42
- REPL $300.41
- P/E Ratio
- PDS $4.71
- REPL N/A
- Revenue Growth
- PDS N/A
- REPL N/A
- 52 Week Low
- PDS $54.49
- REPL $4.92
- 52 Week High
- PDS $79.07
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PDS 30.72
- REPL 62.26
- Support Level
- PDS $59.06
- REPL $13.33
- Resistance Level
- PDS $61.37
- REPL $14.52
- Average True Range (ATR)
- PDS 1.95
- REPL 0.93
- MACD
- PDS -0.99
- REPL 0.22
- Stochastic Oscillator
- PDS 8.09
- REPL 85.16
About PDS Precision Drilling Corporation
Precision Drilling Corpd is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.